110 related articles for article (PubMed ID: 27814880)
1. Commentary on "RNA biomarkers associated with metastatic progression in prostate cancer: A multi-institutional high-throughput analysis of SChLAP1." Prensner JR, Zhao S, Erho N, Schipper M, Iyer MK, Dhanasekaran SM, Magi-Galluzzi C, Mehra R, Sahu A, Siddiqui J, Davicioni E, Den RB, Dicker AP, Karnes RJ, Wei JT, Klein EA, Jenkins RB, Chinnaiyan AM, Feng FY, University of Washington-Urology, Seattle, WA. Lancet Oncol 2014; 15(13):1469-80.
Lin D
Urol Oncol; 2016 Nov; 34(11):521-522. PubMed ID: 27814880
[No Abstract] [Full Text] [Related]
2. Commentary on "The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer." Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JM, Pauwels J, Park K, Kossai M, MacDonald TY, Fontugne J, Erho N, Vergara IA, Ghadessi M, Davicioni E, Jenkins RB, Palanisamy N, Chen Z, Nakagawa S, Hirose T, Bander NH, Beltran H, Fox AH, Elemento O, Rubin MA, University of Washington-Urology, Seattle, WA. Nat Commun 2014; 5:5383.
Lin D
Urol Oncol; 2016 Nov; 34(11):522. PubMed ID: 27814882
[No Abstract] [Full Text] [Related]
3. Commentary on "Integrative clinical genomics of advanced prostate cancer". Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.Cell. 21 May 2015;161(5):1215-1228.
Freedland SJ; Aronson WJ
Urol Oncol; 2017 Aug; 35(8):535. PubMed ID: 28623072
[TBL] [Abstract][Full Text] [Related]
4. Commentary on: "Satisfaction with information used to choose prostate cancer treatment." Gilbert SM, Sanda MG, Dunn RL, Greenfield TK, Hembroff L, Klein E, Saigal CS, Pisters L, Michalski J, Sandler HM, Litwin MS, Wei JT. H. Lee Moffitt Cancer Center, Tampa, Florida; Department of Urology, Emory University, Atlanta, Georgia; Department of Urology, University of Michigan, Ann Arbor, Michigan; Department of Psychiatry and Public Health Institute, University of California-San Francisco, California; Institute for Public Policy and Social Research, Michigan State University, Lansing, Michigan; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio; Department of Urology and Department of Health Policy and Management, University of California-Los Angeles, Los Angeles, California; Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri; Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California.: J Urol 2014;191(5):1265-71. doi:10.1016/j.juro.2013.12.008. [Epub 2013 Dec 12].
Brent H
Urol Oncol; 2016 May; 34(5):247-8. PubMed ID: 25990613
[TBL] [Abstract][Full Text] [Related]
5. A novel RNA in situ hybridization assay for the long noncoding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer.
Mehra R; Shi Y; Udager AM; Prensner JR; Sahu A; Iyer MK; Siddiqui J; Cao X; Wei J; Jiang H; Feng FY; Chinnaiyan AM
Neoplasia; 2014 Dec; 16(12):1121-7. PubMed ID: 25499224
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer.
Mehra R; Udager AM; Ahearn TU; Cao X; Feng FY; Loda M; Petimar JS; Kantoff P; Mucci LA; Chinnaiyan AM
Eur Urol; 2016 Oct; 70(4):549-552. PubMed ID: 26724257
[TBL] [Abstract][Full Text] [Related]
7. A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
Chua MLK; Lo W; Pintilie M; Murgic J; Lalonde E; Bhandari V; Mahamud O; Gopalan A; Kweldam CF; van Leenders GJLH; Verhoef EI; Hoogland AM; Livingstone J; Berlin A; Dal Pra A; Meng A; Zhang J; Orain M; Picard V; Hovington H; Bergeron A; Lacombe L; Fradet Y; Têtu B; Reuter VE; Fleshner N; Fraser M; Boutros PC; van der Kwast TH; Bristow RG
Eur Urol; 2017 Nov; 72(5):665-674. PubMed ID: 28511883
[TBL] [Abstract][Full Text] [Related]
8. Commentary on: "Inherited DNA-repair gene mutations in men with metastatic prostate cancer." Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016 Aug 4;375(5):443-53.
Lee BH
Urol Oncol; 2017 Sep; 35(9):575-576. PubMed ID: 28789927
[TBL] [Abstract][Full Text] [Related]
9. Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer.
Mouraviev V; Lee B; Patel V; Albala D; Johansen TE; Partin A; Ross A; Perera RJ
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):14-20. PubMed ID: 26503110
[TBL] [Abstract][Full Text] [Related]
10. Re: The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex.
Atala A
J Urol; 2014 Aug; 192(2):613. PubMed ID: 25035039
[No Abstract] [Full Text] [Related]
11. Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer.
White NM; Zhao SG; Zhang J; Rozycki EB; Dang HX; McFadden SD; Eteleeb AM; Alshalalfa M; Vergara IA; Erho N; Arbeit JM; Karnes RJ; Den RB; Davicioni E; Maher CA
Eur Urol; 2017 Feb; 71(2):257-266. PubMed ID: 27460352
[TBL] [Abstract][Full Text] [Related]
12. Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer.
Smolle MA; Bauernhofer T; Pummer K; Calin GA; Pichler M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241429
[TBL] [Abstract][Full Text] [Related]
13. Commentary on "A large-scale analysis of genetic variants within putative miRNA binding sites in prostate cancer." Stegeman S, Amankwah E, Klein K, O'Mara TA, Kim D, Lin HY, Permuth-Wey J, Sellers TA, Srinivasan S, Eeles R, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pharoah P, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Kaneva R, Teixeira MR, PRACTICAL Consortium, Australian Prostate Cancer BioResource, Spurdle AB, Clements JA, Park JY, Batra J, University of Washington-Urology, Seattle, WA. Cancer Discov 2015; 5(4):368-79.
Lin D
Urol Oncol; 2016 Nov; 34(11):522-523. PubMed ID: 27814883
[No Abstract] [Full Text] [Related]
14. Long Non-Coding RNA as Potential Biomarker for Prostate Cancer: Is It Making a Difference?
Deng J; Tang J; Wang G; Zhu YS
Int J Environ Res Public Health; 2017 Mar; 14(3):. PubMed ID: 28272371
[TBL] [Abstract][Full Text] [Related]
15. Commentary on "Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer." Hong MK, Macintyre G, Wedge DC, Van Loo P, Patel K, Lunke S, Alexandrov LB, Sloggett C, Cmero M, Marass F, Tsui D, Mangiola S, Lonie A, Naeem H, Sapre N, Phal PM, Kurganovs N, Chin X, Kerger M, Warren AY, Neal D, Gnanapragasam V, Rosenfeld N, Pedersen JS, Ryan A, Haviv I, Costello AJ, Corcoran NM, Hovens CM, University of Washington-Urology, Seattle, WA. Nat Commun 2015; 6:6605.
Lin D
Urol Oncol; 2016 Nov; 34(11):521. PubMed ID: 27814881
[No Abstract] [Full Text] [Related]
16. Re: Eric A. Klein, Matthew R. Cooperberg, Cristina Magi-Galluzzi, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur urol 2014;66:550-60.
Tolkach Y; Kuczyk M; Imkamp F
Eur Urol; 2014 Dec; 66(6):e115-6. PubMed ID: 25139198
[No Abstract] [Full Text] [Related]
17. The emerging role of noncoding RNA in prostate cancer progression and its implication on diagnosis and treatment.
Takayama K; Inoue S
Brief Funct Genomics; 2016 May; 15(3):257-65. PubMed ID: 26685282
[TBL] [Abstract][Full Text] [Related]
18. Re: Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival: A. Abugharib, W. C. Jackson, V. Tumati, R. T. Dess, J. Y. Lee, S. G. Zhao, M. Soliman, Z. S. Zumsteg, R. Mehra, F. Y. Feng, T. M. Morgan, N. Desai and D. E. Spratt J Urol 2017;197:662-668.
Taguchi S; Fukuhara H; Homma Y
J Urol; 2017 Jul; 198(1):212-214. PubMed ID: 28384440
[No Abstract] [Full Text] [Related]
19. Commentary on: "Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial." Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, CA184-043 Investigators. Departments of Urology and Immunology and Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA, Electronic address: kwon.eugene@mayo.edu; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Brady Urological Institute, Baltimore, MD, USA; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA; Institut Gustave Roussy, University of Paris-Sud, Villejuif, France; Institut Gustave Roussy, Villejuif, France; VU University Medical Centre, Amsterdam, Netherlands; Vienna General Hospital, Medical University Vienna, Vienna, Austria; Institut Bergonié, Bordeaux, France; CHU Caremeau, Nimes, France; Centro Médico Austral, Buenos Aires, Argentina; Centre Jean Perrin, Clermont-Ferrand, France; St John of God Hospital, Subiaco, WA, Australia; University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy; Hospital de Caridade de Ijuí, Ijuí, Brazil; Nottingham University Hospital, Nottingham, UK; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Institute of Oncology Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania; Hospital Británico de Buenos Aires, Buenos Aires, Argentina; Herlev Hospital, Herlev, Denmark; Odense University Hospital, Odense, Denmark; University of Texas MD Anderson Cancer Center, Houston,
Trump D
Urol Oncol; 2016 May; 34(5):249-50. PubMed ID: 25907621
[TBL] [Abstract][Full Text] [Related]
20. Circulating Long Noncoding RNA as a Potential Target for Prostate Cancer.
Su YJ; Yu J; Huang YQ; Yang J
Int J Mol Sci; 2015 Jun; 16(6):13322-38. PubMed ID: 26110379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
